首页 > 最新文献

Recent patents on anti-infective drug discovery最新文献

英文 中文
MERS-CoV An Emerging Viral Zoonotic Disease: Three Years After and Counting. MERS-CoV 一种新出现的病毒性人畜共患病:三年后的今天
Q3 Medicine Pub Date : 2015-04-15
Ziad A Memish
{"title":"MERS-CoV An Emerging Viral Zoonotic Disease: Three Years After and Counting.","authors":"Ziad A Memish","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":" ","pages":"None"},"PeriodicalIF":0.0,"publicationDate":"2015-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33219653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rabies in South Asia: fighting for elimination. 南亚狂犬病:为消除而战。
Q3 Medicine Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150410130024
Fazle-Rabbi Chowdhury, Ariful Basher, Mohammad R Amin, Nazia Hassan, Mohammad I Patwary

South Asia is regarded as the hot spot for the tourist and travelers. Unfortunately, three big countries (India, Pakistan and Bangladesh) of this region belong to top five rabies endemic countries of the world. Around 55,000 people die of rabies every year globally and 45% of them belong to South and South East Asia. Countries are now working on the elimination of rabies by the year 2020. Elimination of animal rabies is the pivotal of controlling human rabies. Dog (primary source) registration, population control and mass vaccination are the different ways of eliminating animal rabies. Pre (for risk groups including travelers) and post-exposure vaccine is the core for controlling human rabies. Post-exposure vaccine consists of nerve tissue vaccine and tissue culture vaccine. Due to low antigenicity and post-vaccine neurological complications all countries of South Asia except Pakistan have phased out the production and use of nerve tissue vaccine. To reduce the cost intramuscular regimen is now largely replaced by intradermal regimen and equine rabies immunoglobulin will probably replace human immunoglobulin in future for category III animal bite. 'SAARC' took initiatives for rabies elimination through 'SAARC development fund' which would hopefully play a vital role in regional collaboration to make the region rabies free.

南亚被认为是旅游和旅行者的热点。不幸的是,该地区的三个大国(印度、巴基斯坦和孟加拉国)属于世界五大狂犬病流行国家。全球每年约有5.5万人死于狂犬病,其中45%发生在南亚和东南亚。各国目前正在努力到2020年消除狂犬病。消灭动物狂犬病是控制人类狂犬病的关键。犬(主要来源)登记、人口控制和大规模疫苗接种是消除动物狂犬病的不同方法。暴露前(针对包括旅行者在内的危险群体)和暴露后疫苗是控制人类狂犬病的核心。暴露后疫苗包括神经组织疫苗和组织培养疫苗。由于抗原性低和疫苗后神经系统并发症,除巴基斯坦外,所有南亚国家都已逐步停止生产和使用神经组织疫苗。为了降低成本,肌内注射疗法现在已被皮内注射疗法所取代,马狂犬病免疫球蛋白将来可能会取代人类免疫球蛋白用于III类动物咬伤。“南盟”通过“南盟发展基金”采取了消除狂犬病的举措,该基金有望在区域合作中发挥重要作用,使该地区无狂犬病。
{"title":"Rabies in South Asia: fighting for elimination.","authors":"Fazle-Rabbi Chowdhury,&nbsp;Ariful Basher,&nbsp;Mohammad R Amin,&nbsp;Nazia Hassan,&nbsp;Mohammad I Patwary","doi":"10.2174/1574891x10666150410130024","DOIUrl":"https://doi.org/10.2174/1574891x10666150410130024","url":null,"abstract":"<p><p>South Asia is regarded as the hot spot for the tourist and travelers. Unfortunately, three big countries (India, Pakistan and Bangladesh) of this region belong to top five rabies endemic countries of the world. Around 55,000 people die of rabies every year globally and 45% of them belong to South and South East Asia. Countries are now working on the elimination of rabies by the year 2020. Elimination of animal rabies is the pivotal of controlling human rabies. Dog (primary source) registration, population control and mass vaccination are the different ways of eliminating animal rabies. Pre (for risk groups including travelers) and post-exposure vaccine is the core for controlling human rabies. Post-exposure vaccine consists of nerve tissue vaccine and tissue culture vaccine. Due to low antigenicity and post-vaccine neurological complications all countries of South Asia except Pakistan have phased out the production and use of nerve tissue vaccine. To reduce the cost intramuscular regimen is now largely replaced by intradermal regimen and equine rabies immunoglobulin will probably replace human immunoglobulin in future for category III animal bite. 'SAARC' took initiatives for rabies elimination through 'SAARC development fund' which would hopefully play a vital role in regional collaboration to make the region rabies free. </p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":"10 1","pages":"30-4"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150410130024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33078410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
The Human Epidermal Antimicrobial Barrier: Current Knowledge, Clinical Relevance and Therapeutic Implications. 人类表皮抗菌屏障:当前的知识,临床相关性和治疗意义。
Q3 Medicine Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150623093446
Roshan Gunathilake

Most of the defensive functions of the human skin are localized to the stratum corneum (SC), the outermost layer of the epidermis consisting of several layers of cornified keratinocytes embedded in a lipid matrix. Included in the armamentarium of the epidermal barrier against microbial invasion are surface pH, SC lipids, specialized antimicrobial peptides such as defensins and cathelicidins, enzymes and enzyme inhibitors, chemokines, and epidermal Toll-like receptors. Multiple epidermal defensive mechanisms are co-localized, coregulated, and intertwined. The purpose of this review is to discuss patents and to describe the current knowledge that concerns the role of the epidermis as an antimicrobial barrier, outlining potential clinical and therapeutic implications.

人类皮肤的大部分防御功能都定位于角质层(SC),角质层是表皮的最外层,由嵌入在脂质基质中的几层角质形成细胞组成。表皮屏障包括表面pH值、SC脂质、特殊抗菌肽(如防御素和抗菌肽)、酶和酶抑制剂、趋化因子和表皮toll样受体。多种表皮防御机制是共定位、共调节和相互交织的。本综述的目的是讨论专利,并描述当前关于表皮作为抗菌屏障作用的知识,概述潜在的临床和治疗意义。
{"title":"The Human Epidermal Antimicrobial Barrier: Current Knowledge, Clinical Relevance and Therapeutic Implications.","authors":"Roshan Gunathilake","doi":"10.2174/1574891x10666150623093446","DOIUrl":"https://doi.org/10.2174/1574891x10666150623093446","url":null,"abstract":"<p><p>Most of the defensive functions of the human skin are localized to the stratum corneum (SC), the outermost layer of the epidermis consisting of several layers of cornified keratinocytes embedded in a lipid matrix. Included in the armamentarium of the epidermal barrier against microbial invasion are surface pH, SC lipids, specialized antimicrobial peptides such as defensins and cathelicidins, enzymes and enzyme inhibitors, chemokines, and epidermal Toll-like receptors. Multiple epidermal defensive mechanisms are co-localized, coregulated, and intertwined. The purpose of this review is to discuss patents and to describe the current knowledge that concerns the role of the epidermis as an antimicrobial barrier, outlining potential clinical and therapeutic implications. </p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":"10 2","pages":"84-97"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150623093446","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33409782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Challenges for Fish Foodborne Parasitic Zoonotic Diseases. 鱼类食源性寄生虫人畜共患病的挑战。
Q3 Medicine Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150504120415
Alfonso J Rodríguez-Morales
{"title":"Challenges for Fish Foodborne Parasitic Zoonotic Diseases.","authors":"Alfonso J Rodríguez-Morales","doi":"10.2174/1574891x10666150504120415","DOIUrl":"https://doi.org/10.2174/1574891x10666150504120415","url":null,"abstract":"","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":"10 1","pages":"3-5"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150504120415","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33329180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Antibiotic Susceptibility Patterns of Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase Pseudomonas aeruginosa Clinical Isolates. 广谱β -内酰胺酶与非广谱β -内酰胺酶铜绿假单胞菌临床分离株的药敏特征
Q3 Medicine Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150901111312
Mostafa Akbariqomi, Sobhan Ghafourian, Morovat Taherikalani, Satar Mohammadi, Iraj Pakzad, Nourkhoda Sadeghifard

Background: Pseudomonas aeruginosa is known as an opportunistic pathogen responsible for nosocomial infections. Multidrug (MDR) resistance bacteria are considered as a worldwide issue. The current research goal to investigate the antibiotic susceptibility pattern in Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase producing P. aeruginosa clinical isolates.

Methods: A total of 76 P.aeruginosa clinical isolates were collected from Milad hospital in Tehran, Iran, during 8 months period in 2012. P.aeruginosa clinical isolates were subjected for ESBL production by phenotypic methods. The antibiotic susceptibility patterns were identified in ESBL and non-ESBL P. aeruginosa by MIC.

Results: our results demonstrated that 76.3% (n =58) isolates were resistant to more than three antibiotics and classified as MDR. The majority of MDR strains were found in ESBL producer P. aeruginosa. ceftazidim as 3rd generation of cephalosporins, ciprofloxacin, Ticarcillin and aztreonam were found as a base for definition of MDR in the current research. The effectiveness antibiotics against ESBL and non-ESBL were meropenem and amikacin, respectively.

Conclusion: based on our knowledge obtained from results, both ESBL and non-ESBL P. aeruginosa were resistant to extended antibiotics and this is a major health care problem. On the other hand, MDR strains more identified in ESBL producer P .a eruginosa. Also, carabapenem resistance observed in non-ESBL producer strains. Hence, it is recommended that the MDR strains should be following up. the prescription of ceftazidim, ciprofloxacin, Ticarcillin and aztreonam should be limited.

背景:铜绿假单胞菌被认为是一种导致医院感染的机会性病原体。耐多药细菌被认为是一个世界性的问题。本研究的目的是探讨广谱β -内酰胺酶和不产生广谱β -内酰胺酶的铜绿假单胞菌临床分离株的药敏模式。方法:2012年8个月在伊朗德黑兰Milad医院收集76株铜绿假单胞菌临床分离株。采用表型方法对铜绿假单胞菌临床分离株进行ESBL生产。通过MIC鉴定了ESBL和非ESBL铜绿假单胞菌的抗生素敏感性模式。结果:76.3% (n =58)株对3种以上抗生素耐药,属MDR;大多数耐多药菌株被发现在ESBL生产者铜绿假单胞菌。本研究发现头孢他啶作为第三代头孢菌素与环丙沙星、替卡西林、氨曲南作为MDR定义的基础。对ESBL和非ESBL有效的抗生素分别为美罗培南和阿米卡星。结论:根据我们从结果中获得的知识,ESBL和非ESBL铜绿假单胞菌都对扩展抗生素耐药,这是一个主要的卫生保健问题。另一方面,耐多药菌株更多地在ESBL生产者P .a . eruginosa中发现。此外,在非esbl产生菌株中也观察到对卡拉青霉烯的耐药性。因此,建议对耐多药菌株进行随访。限制头孢他啶、环丙沙星、替卡西林、氨曲南处方。
{"title":"Antibiotic Susceptibility Patterns of Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase Pseudomonas aeruginosa Clinical Isolates.","authors":"Mostafa Akbariqomi,&nbsp;Sobhan Ghafourian,&nbsp;Morovat Taherikalani,&nbsp;Satar Mohammadi,&nbsp;Iraj Pakzad,&nbsp;Nourkhoda Sadeghifard","doi":"10.2174/1574891x10666150901111312","DOIUrl":"https://doi.org/10.2174/1574891x10666150901111312","url":null,"abstract":"<p><strong>Background: </strong>Pseudomonas aeruginosa is known as an opportunistic pathogen responsible for nosocomial infections. Multidrug (MDR) resistance bacteria are considered as a worldwide issue. The current research goal to investigate the antibiotic susceptibility pattern in Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase producing P. aeruginosa clinical isolates.</p><p><strong>Methods: </strong>A total of 76 P.aeruginosa clinical isolates were collected from Milad hospital in Tehran, Iran, during 8 months period in 2012. P.aeruginosa clinical isolates were subjected for ESBL production by phenotypic methods. The antibiotic susceptibility patterns were identified in ESBL and non-ESBL P. aeruginosa by MIC.</p><p><strong>Results: </strong>our results demonstrated that 76.3% (n =58) isolates were resistant to more than three antibiotics and classified as MDR. The majority of MDR strains were found in ESBL producer P. aeruginosa. ceftazidim as 3rd generation of cephalosporins, ciprofloxacin, Ticarcillin and aztreonam were found as a base for definition of MDR in the current research. The effectiveness antibiotics against ESBL and non-ESBL were meropenem and amikacin, respectively.</p><p><strong>Conclusion: </strong>based on our knowledge obtained from results, both ESBL and non-ESBL P. aeruginosa were resistant to extended antibiotics and this is a major health care problem. On the other hand, MDR strains more identified in ESBL producer P .a eruginosa. Also, carabapenem resistance observed in non-ESBL producer strains. Hence, it is recommended that the MDR strains should be following up. the prescription of ceftazidim, ciprofloxacin, Ticarcillin and aztreonam should be limited.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":"10 2","pages":"128-33"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33964116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Chikungunya, the 2014, emerging infectious diseases in the Americas. 基孔肯雅热是2014年美洲新发传染病。
Q3 Medicine Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150408155316
Celia M Alpuche-Aranda, Hugo Lopez-Gatell
{"title":"Chikungunya, the 2014, emerging infectious diseases in the Americas.","authors":"Celia M Alpuche-Aranda,&nbsp;Hugo Lopez-Gatell","doi":"10.2174/1574891x10666150408155316","DOIUrl":"https://doi.org/10.2174/1574891x10666150408155316","url":null,"abstract":"","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":"10 1","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150408155316","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33197354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Malaria by Plasmodium knowlesi, A Zoonosis Transmitted by Vectors. 诺氏疟原虫感染的疟疾,一种由媒介传播的人畜共患病。
Q3 Medicine Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150408155455
Jorge E Machado-Alba
{"title":"Malaria by Plasmodium knowlesi, A Zoonosis Transmitted by Vectors.","authors":"Jorge E Machado-Alba","doi":"10.2174/1574891x10666150408155455","DOIUrl":"https://doi.org/10.2174/1574891x10666150408155455","url":null,"abstract":"","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":"10 1","pages":"8-9"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150408155455","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33197355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human anthrax as a re-emerging disease. 人类炭疽是一种重新出现的疾病。
Q3 Medicine Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150408162354
Mehmet Doganay, Hayati Demiraslan

Anthrax is primarily a disease of herbivores and the etiological agent is B. anthracis which is a gram-positive, aerobic, spore-forming, and rod shaped bacterium. Bacillus anthracis spores are highly resistant to heat, pressure, ultraviolet and ionizing radiation, chemical agents and disinfectants. For these reasons, B. anthracis spores are an attractive choice as biological agents for the use of bioweapon and/or bioterrorism. Soil is the main reservoir for the infectious agent. The disease most commonly affects wild and domestic mammals. Human are secondarily infected by contact with infected animals and contaminated animal products or directly expose to B. anthracis spores. Anthrax occurs worldwide. This infection is still endemic or hyperendemic in both animals and humans in some part of areas of the world; particularly in Middle East, West Africa, Central Asia, some part of India, South America. However, some countries are claiming free of anthrax, and anthrax has become a re-emerging disease in western countries with the intentional outbreak. Currently, anthrax is classified according to its setting as (1) naturally occurring anthrax, (2) bioterrorism-related anthrax. Vast majority of human anthrax are occurring as naturally occurring anthrax in the world. It is also a threaten disease for western countries. The aim of this paper is to review the relevant patents, short historical perspective, microbiological and epidemiological features, clinical presentations and treatment.

炭疽主要是食草动物的疾病,病原体是炭疽杆菌,这是一种革兰氏阳性,需氧,孢子形成,棒状细菌。炭疽芽孢杆菌孢子对高温、高压、紫外线和电离辐射、化学制剂和消毒剂具有很强的抵抗力。由于这些原因,炭疽芽孢杆菌孢子作为生物武器和/或生物恐怖主义的生物制剂是一个有吸引力的选择。土壤是传染因子的主要储存库。这种疾病最常见于野生和家养哺乳动物。人类通过接触受感染的动物和受污染的动物产品或直接暴露于炭疽芽孢杆菌孢子而继发感染。炭疽热在世界各地都有发生。在世界某些地区,这种感染在动物和人类中仍然是地方性或高地方性的;特别是在中东、西非、中亚、印度部分地区和南美洲。然而,一些国家声称没有炭疽,炭疽在西方国家已成为一种重新出现的疾病。目前,炭疽根据其设定分为(1)自然发生的炭疽,(2)与生物恐怖主义有关的炭疽。世界上绝大多数的人类炭疽是自然发生的炭疽。它也是西方国家的一种威胁疾病。本文就其相关专利、近期历史、微生物学和流行病学特征、临床表现和治疗进行综述。
{"title":"Human anthrax as a re-emerging disease.","authors":"Mehmet Doganay,&nbsp;Hayati Demiraslan","doi":"10.2174/1574891x10666150408162354","DOIUrl":"https://doi.org/10.2174/1574891x10666150408162354","url":null,"abstract":"<p><p>Anthrax is primarily a disease of herbivores and the etiological agent is B. anthracis which is a gram-positive, aerobic, spore-forming, and rod shaped bacterium. Bacillus anthracis spores are highly resistant to heat, pressure, ultraviolet and ionizing radiation, chemical agents and disinfectants. For these reasons, B. anthracis spores are an attractive choice as biological agents for the use of bioweapon and/or bioterrorism. Soil is the main reservoir for the infectious agent. The disease most commonly affects wild and domestic mammals. Human are secondarily infected by contact with infected animals and contaminated animal products or directly expose to B. anthracis spores. Anthrax occurs worldwide. This infection is still endemic or hyperendemic in both animals and humans in some part of areas of the world; particularly in Middle East, West Africa, Central Asia, some part of India, South America. However, some countries are claiming free of anthrax, and anthrax has become a re-emerging disease in western countries with the intentional outbreak. Currently, anthrax is classified according to its setting as (1) naturally occurring anthrax, (2) bioterrorism-related anthrax. Vast majority of human anthrax are occurring as naturally occurring anthrax in the world. It is also a threaten disease for western countries. The aim of this paper is to review the relevant patents, short historical perspective, microbiological and epidemiological features, clinical presentations and treatment. </p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":"10 1","pages":"10-29"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150408162354","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33197375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 50
Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels. 用强力霉素治疗的登革热患者显示出与IL-6和TNF水平降低相关的较低死亡率。
Q3 Medicine Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150410153839
Terry M Fredeking, Jorge E Zavala-Castro, Pedro González-Martínez, William Moguel-Rodríguez, Ernesto C Sanchez, Michael J Foster, Fredi A Diaz-Quijano

Objective: To determine the effect of doxycycline treatment on cytokine levels, including tumor necrosis factor (TNF) and interleukin 6 (IL-6), and mortality in dengue patients at high risk of complication.

Methods: A group of dengue hemorrhagic fever patients (n=231) were randomized to receive either standard supportive care or supportive care in addition to oral doxycycline twice daily for 7 days. Dengue virus infection was confirmed by PCR using multiple primers. Serum samples were obtained at days 0, 3, 5 and 7 and tested for levels of TNF and IL-6.

Results: Doxycycline-treated group presented a 46% lower mortality than that observed in the untreated group (11.2% [13/116] vs 20.9% [24/115], respectively, p=0.05). Moreover, administration of doxycycline resulted in a significant (p<0.01) decrease in levels of TNF and IL-6 versus controls in the tests performed during follow-up (day 3, 5 and 7). Patients who died in both groups possessed significantly (p<0.01) higher levels of TNF and IL-6 compared to those who survived at all-time points.

Conclusion: The above findings suggest that doxycycline can provide a clinical benefit to dengue patients at high risk of complications. This effect could be mediated by decreasing pro-inflammatory cytokine levels.

目的:探讨强力霉素治疗对登革热高危并发症患者肿瘤坏死因子(TNF)、白细胞介素6 (IL-6)水平及死亡率的影响。方法:一组登革热出血热患者(n=231)随机分为两组,一组接受标准支持治疗,另一组在支持治疗的基础上每天口服强力霉素2次,连续7天。采用多引物PCR检测登革病毒感染。在第0、3、5和7天采集血清样本,检测TNF和IL-6的水平。结果:多西环素治疗组的死亡率比未治疗组低46% (11.2% [13/116]vs 20.9% [24/115], p=0.05)。结论:以上结果提示多西环素对登革热高危并发症患者具有临床益处。这种作用可能是通过降低促炎细胞因子水平介导的。
{"title":"Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels.","authors":"Terry M Fredeking,&nbsp;Jorge E Zavala-Castro,&nbsp;Pedro González-Martínez,&nbsp;William Moguel-Rodríguez,&nbsp;Ernesto C Sanchez,&nbsp;Michael J Foster,&nbsp;Fredi A Diaz-Quijano","doi":"10.2174/1574891x10666150410153839","DOIUrl":"https://doi.org/10.2174/1574891x10666150410153839","url":null,"abstract":"<p><strong>Objective: </strong>To determine the effect of doxycycline treatment on cytokine levels, including tumor necrosis factor (TNF) and interleukin 6 (IL-6), and mortality in dengue patients at high risk of complication.</p><p><strong>Methods: </strong>A group of dengue hemorrhagic fever patients (n=231) were randomized to receive either standard supportive care or supportive care in addition to oral doxycycline twice daily for 7 days. Dengue virus infection was confirmed by PCR using multiple primers. Serum samples were obtained at days 0, 3, 5 and 7 and tested for levels of TNF and IL-6.</p><p><strong>Results: </strong>Doxycycline-treated group presented a 46% lower mortality than that observed in the untreated group (11.2% [13/116] vs 20.9% [24/115], respectively, p=0.05). Moreover, administration of doxycycline resulted in a significant (p<0.01) decrease in levels of TNF and IL-6 versus controls in the tests performed during follow-up (day 3, 5 and 7). Patients who died in both groups possessed significantly (p<0.01) higher levels of TNF and IL-6 compared to those who survived at all-time points.</p><p><strong>Conclusion: </strong>The above findings suggest that doxycycline can provide a clinical benefit to dengue patients at high risk of complications. This effect could be mediated by decreasing pro-inflammatory cytokine levels.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":"10 1","pages":"51-8"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150410153839","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33202365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 61
Preface. 前言。
Q3 Medicine Pub Date : 2015-01-01 DOI: 10.2174/1574891x1001150521150210
Dieter Kabelitz
{"title":"Preface.","authors":"Dieter Kabelitz","doi":"10.2174/1574891x1001150521150210","DOIUrl":"https://doi.org/10.2174/1574891x1001150521150210","url":null,"abstract":"","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":"10 1","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x1001150521150210","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34031651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Recent patents on anti-infective drug discovery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1